AC ImmuneACIU -0.79%25 3-Year RORE % is 6.81 as of Mar. 2026. GuruFocus rates ACIU with a GF Score™ of 25/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,287 Biotechnology companies, AC Immune ranks better than 70.63% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
AC Immune's 3-Year RORE % for the quarter that ended in Mar. 2026 was 6.81%.
The industry rank for AC Immune's 3-Year RORE % or its related term are showing as below:
ACIU's 3-Year RORE % is ranked better than 70.63% of 1287
companies
in the Biotechnology industry
Industry Median: -11.53
vs ACIU: 6.81
AC Immune (NAS:ACIU) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
AC Immune 3-Year RORE % Related Terms
AC Immune 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for AC Immune's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIU vs NAUT, IVVD, OTLK: 3-Year RORE % Comparison
For the Biotechnology subindustry, AC Immune's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AC Immune 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AC Immune's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where AC Immune's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
AC Immune (ACIU) has a 3-Year RORE % of 6.81 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on AC Immune and its competitors. According to the industry distribution chart, AC Immune ranks #378 out of 1287 companies in the Biotechnology industry, placing it in the top 29.4%.
Is AC Immune's 3-Year RORE % too high?
AC Immune's current 3-Year RORE % is 6.81. Based on the distribution chart, AC Immune ranks #378 out of 1287 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AC Immune has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's 3-Year RORE % compare to NAUT and IVVD?
According to the Biotechnology industry distribution chart, AC Immune ranks #378 out of 1287 companies for 3-Year RORE %. This puts AC Immune in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on AC Immune and its competitors. AC Immune's current 3-Year RORE % is 6.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.51 — trading 234.7% above its estimated fair value. The current 3-Year RORE % is 6.81. AC Immune's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For AC Immune (ACIU), the current 3-Year RORE % is 6.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AC Immune (ACIU) Overvalued in 2026?
Based on GuruFocus' analysis, AC Immune stock appears to be overvalued.
The current stock price of $2.51 is trading 234.7% above its estimated GF Value™ of $0.75.
GuruFocus considers AC Immune to be Significantly Overvalued.
Key valuation signals for ACIU:
3-Year RORE %: 6.81
GF Value™: $0.75 vs. price of $2.51 (234.7% above fair value)
No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
25GF Score
Get the complete analysis for ACIU
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIU has been successfully added to your 
